Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack F Bukowski

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Annals of the Rheumatic Diseases|October 4, 2017
Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritisMaxime Dougados, Walter P Maksymowych, Robert B M Landewé, et al.
Arthritis Care & Research|May 9, 2017
Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled StudyMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2014
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Arthritis Research & Therapy|May 25, 2019
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trialIvan Foeldvari, Tamàs Constantin, Jelena Vojinović, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Annals of the Rheumatic Diseases|October 4, 2017
Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritisMaxime Dougados, Walter P Maksymowych, Robert B M Landewé, et al.
Arthritis Care & Research|May 9, 2017
Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled StudyMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2014
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Arthritis Research & Therapy|May 25, 2019
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trialIvan Foeldvari, Tamàs Constantin, Jelena Vojinović, et al.
Pageof 3